Reply to Paul and Leibovici.

Boucher, Helen W; Ambrose, Paul G; Chambers, Henry F; Ebright, Richard H; Jezek, Amanda; Murray, Barbara E; Ostrowsky, Belinda; Rex, John H

Boucher, Helen W; Ambrose, Paul G; Chambers, Henry F; Ebright, Richard H; Jezek, Amanda; Murray, Barbara E; Ostrowsky, Belinda; Rex, John H.

Afiliación

Boucher HW; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Ambrose PG; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Chambers HF; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Ebright RH; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Jezek A; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Murray BE; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Ostrowsky B; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.
Rex JH; Tufts Medical Center, Infectious Diseases, Boston, Massachusetts, US.

J Infect Dis ; 217(3): 509-510, 2018 01 17.

Article en En | MEDLINE | ID: mdl-29240925

Asunto(s)

Desarrollo de Medicamentos; Farmacorresistencia Bacteriana; Resistencia a Múltiples Medicamentos; Bacterias

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Múltiples Medicamentos / Farmacorresistencia Bacteriana / Desarrollo de Medicamentos Idioma: En Revista: J Infect Dis Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google